News, Short Squeeze, Breakout and More Instantly...
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies - Amends existing protocol of ongoing Phase 1 study in R/R NHL - - Initial data expected in the fourth quarter of 2021 - P...
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes - Phase 2 study sponsored by investigators at Universität Leipzig in Germany - ...
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference PR Newswire LEXINGTON, Mass. , Jan. 14, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment o...